Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

Bayani, Jane ; Poncet, Coralie ; Crozier, Cheryl ; Neven, Anouk ; Piper, Tammy ; Cunningham, Carrie ; Sobol, Monika ; Aebi, Stefan ; Benstead, Kim and Bogler, Oliver , et al. (2021) In npj Breast Cancer 7(1).
Abstract

Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 (retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString™ panel comprised of the genes from the commercial risk tests Prosigna®, OncotypeDX®, and MammaPrint®, risk scores and intrinsic subtyping data were generated to... (More)

Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 (retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString™ panel comprised of the genes from the commercial risk tests Prosigna®, OncotypeDX®, and MammaPrint®, risk scores and intrinsic subtyping data were generated to recapitulate the commercial tests as described by us previously. We also examined the prognostic value of other risk scores such as the Genomic Grade Index (GGI), IHC4-mRNA and our prognostic 95-gene signature. In this sample set of male BCa, we demonstrated prognostic utility on univariate analysis. Across all signatures, patients whose samples were identified as low-risk experienced better outcomes than intermediate-risk, with those classed as high risk experiencing the poorest outcomes. As seen with female BCa, the concordance between tests was poor, with C-index values ranging from 40.3% to 78.2% and Kappa values ranging from 0.17 to 0.58. To our knowledge, this is the largest study of male breast cancers assayed to generate risk scores of the current commercial and academic risk tests demonstrating comparable clinical utility to female BCa.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
npj Breast Cancer
volume
7
issue
1
article number
98
publisher
Nature Publishing Group
external identifiers
  • scopus:85111629180
  • pmid:34312396
ISSN
2374-4677
DOI
10.1038/s41523-021-00301-0
language
English
LU publication?
yes
id
020b4257-1f13-4bdf-8e1d-74a43468abee
date added to LUP
2021-08-26 13:37:18
date last changed
2024-06-15 15:07:13
@article{020b4257-1f13-4bdf-8e1d-74a43468abee,
  abstract     = {{<p>Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 (retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString™ panel comprised of the genes from the commercial risk tests Prosigna®, OncotypeDX®, and MammaPrint®, risk scores and intrinsic subtyping data were generated to recapitulate the commercial tests as described by us previously. We also examined the prognostic value of other risk scores such as the Genomic Grade Index (GGI), IHC4-mRNA and our prognostic 95-gene signature. In this sample set of male BCa, we demonstrated prognostic utility on univariate analysis. Across all signatures, patients whose samples were identified as low-risk experienced better outcomes than intermediate-risk, with those classed as high risk experiencing the poorest outcomes. As seen with female BCa, the concordance between tests was poor, with C-index values ranging from 40.3% to 78.2% and Kappa values ranging from 0.17 to 0.58. To our knowledge, this is the largest study of male breast cancers assayed to generate risk scores of the current commercial and academic risk tests demonstrating comparable clinical utility to female BCa.</p>}},
  author       = {{Bayani, Jane and Poncet, Coralie and Crozier, Cheryl and Neven, Anouk and Piper, Tammy and Cunningham, Carrie and Sobol, Monika and Aebi, Stefan and Benstead, Kim and Bogler, Oliver and Dal Lago, Lissandra and Fraser, Judith and Hilbers, Florentine and Hedenfalk, Ingrid and Korde, Larissa and Linderholm, Barbro and Martens, John and Middleton, Lavinia and Murray, Melissa and Kelly, Catherine and Nilsson, Cecilia and Nowaczyk, Monika and Peeters, Stephanie and Peric, Aleksandra and Porter, Peggy and Schröder, Carolien and Rubio, Isabel T. and Ruddy, Kathryn J. and van Asperen, Christi and Van Den Weyngaert, Danielle and van Deurzen, Carolien and van Leeuwen-Stok, Elise and Vermeij, Joanna and Winer, Eric and Giordano, Sharon H. and Cardoso, Fatima and Bartlett, John M.S.}},
  issn         = {{2374-4677}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Nature Publishing Group}},
  series       = {{npj Breast Cancer}},
  title        = {{Evaluation of multiple transcriptomic gene risk signatures in male breast cancer}},
  url          = {{http://dx.doi.org/10.1038/s41523-021-00301-0}},
  doi          = {{10.1038/s41523-021-00301-0}},
  volume       = {{7}},
  year         = {{2021}},
}